Continuity Pharma

Yesterday, Gerren McHam from the API Innovation Center participated in a panel discussion on implementing policy to prevent drug shortages, building on our collaborative work with the Duke-Margolis ReVAMP Drug Supply Chain Consortium. This event brought together consortium members and industry leaders in discussions on increasing supply chain reliability and reducing the frequency and severity of drug shortages. The panel, “Enabling Reliability through Advanced Manufacturing Technologies,” included?Mark Godfrey from Eli Lilly and Company, Andrew J. Carpenter, Ph.D., from Phlow, and Joel Welch from the U.S. Food and Drug Administration (FDA), and was moderated by Gerrit Hamre from the Duke-Margolis Institute for Health Policy. They discussed existing federal programs that can drive increased adoption of advanced manufacturing technologies (AMTs) and opportunities for leveraging AMTs for improvements in reliability, quality assurance, and national health security. During the panel, we shared our success story of developing Lomustine API with AMTs and how we will continue to invest in advanced technologies to drive reliability in the supply chain. We're committed to advancing these initiatives to ensure a more reliable and secure pharmaceutical supply chain for all. Thank you to Betsy Baer, US Pharmacopeia, for these photos! #AdvancedManufacturingTechnologies #SupplyChainResilience

Drug shortages in the U.S. have reached a record high, according to data from the American Society of Health-System Pharmacists (ASHP). In the first quarter of 2024, 323 drugs were in active shortage, and many of these shortages have persisted for over two years. This issue reinforces the importance of ensuring access to essential medications for patients across the U.S. and the work the API Innovation Center is doing to create sustainable and efficient routes for producing vital pharmaceuticals in the U.S. to ensure national health. Read the full report from the ASHP here:?https://lnkd.in/gMwfaTqf #DrugShortages #Pharma

The API Innovation Center is proud to announce the release of a collaborative white paper,?A Bold Goal: Reshoring 25% of Small Molecule API to the U.S. in Five Years.?Developed with input from leading #pharma manufacturers, patient advocates and other public health stakeholders, the report urges the public and private sectors to work together to overcome price erosion, industry consolidation and manufacturing offshoring dynamics challenging Americans’ reliable access to essential medications. This report is in response to the White House Office of Science and Technology Policy?bold?goal to re-shore 25% of small-molecule APIs within five years and follows calls for a?new approach?aimed at guaranteeing Americans' reliable access to essential medications. This publication showcases the collaboration within our industry, so we extend our thanks to our panelists and moderators for their contribution:??Adam Fisher, Kurt Karst, Andrea Adamo,?Bill Foley,?Matt Hancock,?Kyle Hoelting, PharmD, BCPS,?Dennis Hall, Stephen Schondelmeyer, PharmD, Ph.D.,?David Thompson, Andrew Gonce,?Edward Price,?Fernando Muzzio,?Karthik Raghavan,?Laura Bray,?Stephen Colvill?,?Marcus Lumpuy?and Bayan Takizawa We also extend our gratitude to?our workgroup leads whose dedication throughout the planning stages of the event helped formulate the direction of the event and paper: Betsy Baer, Elizabeth Bergman, Christopher S. and Gregg Dougan Visit our webpage to download the report: https://lnkd.in/g6a6x5fK